The Need for Transparency and Efficiency in Reimbursement Decisions Relating to Drugs for Rare Diseases

Abstract

Get full access to this article

View all access options for this article.

References

Johnson

Davis

Wang

S-T

. Importance of transparency in assessing the feasibility of modeling rare disease. Med Decis Making. 2015;35(2):143–4.

Coyle

Cheung

Evans

. Opportunity cost of funding drugs for rare diseases: the cost-effectiveness of eculizumab in paroxysmal nocturnal hemoglobinuria. Med Decis Making. 2014;34(8):1016–29.

Hillmen

Muus

Roth

. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013;162(1):62–73.

Kelly

Hill

Arnold

. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117(25):6786–92.

Taylor

Wainwright

. Open label extension studies: research or marketing? BMJ. 2005:331;572–4.

Stalpers

LJA

Van Gasteren

HJM

Van Daal

WAJ

. DEALE-ing with life expectancy and mortality rates. Med Decis Making. 1989;9:150–2.

Beck

Pauker

. Does DEALE-ing stack the deck? Med Decis Making. 1999;19:503–4.

Hillmen

Lewis

Bessler

Luzzatto

Dacie

. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253–8.

Socié

Mary

de Gramont

. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet. 1996;348(9027):573–7.

10.

Levine

Hirsh

Gent

. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet. 1994;343(8902):886–9.

11.

National Institute for Clinical Excellence (NICE). Appraising Life-Extending, End of Life Treatments. London, UK: National Institute for Health and Clinical Excellence; 2009.

12.

Cookson

. Can the NICE “end-of-life premium” be given a coherent ethical justification? Health Polit Policy Law. 2013;38(6):1129–48.

13.

Desser

Gyrd-Hansen

Olsen

Grepperud

Kristiansen

. Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67. BMJ. 2010;341:c4715.

14.

Desser

. Prioritizing treatment of rare diseases: a survey of preferences of Norwegian doctors. Soc Sci Med. 2013;94:56–62.

15.

Linley

Hughes

. Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain. Health Econ. 2013;22(8):948–64.